Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab followed by LNA043 for knee osteoarthritis
2020-003631-21Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of canakinumab and LNA043 in knee osteoarthritis (OA) (4 arms), sponsored by Novartis. Primary endpoint: Change in cartilage volume in the index region measured by MRI. Started May 2021; status: terminated.
02
Drugs
canakinumabLNA043
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2020-003631-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003631-21.